We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Invitrogen Advances Drug Discovery Safety Testing

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Invitrogen Corporation has announced the availability of a proprietary test kit that can enable better screening for cardiotoxicity traits of potential drug compounds earlier in the discovery process.

The Predictor™ hERG Fluorescence Polarization Assay Kit is the first commercially available non-radioactive, homogenous assay kit for high-throughput screening of compounds interacting with the hERG ion channel, the company says.

Drug-induced heart dysrhythmias and adverse effects have been linked with blockage of the human ether-a-go-go related gene (hERG) channel.

Lethal cardiotoxic side effects of several blockbuster drugs have led to the U.S. Food and Drug Administration’s requirement that all new small-molecule drug compounds be tested for hERG channel blockage, typically using a technique called electrophysiology patch-clamp analysis.

Invitrogen says that the Patch-clamp analysis is costly and slow to perform; therefore most companies narrow the number of compounds they test with patch-clamp analysis with screening assays that are less expensive and less time-consuming. Currently, drug developers use radioligand displacement assays as the primary screen for reducing the number of patch-clamp analyses.

Invitrogen’s Predictor™ hERG assay is designed to eliminate radioactivity and allow researchers to triage compounds for more detailed patch-clamp analysis.

In addition, the Predictor™ hERG assay results are highly predictive of patch-clamp data, much faster and considerably less expensive than current radioligand displacement tests, the company claims.